ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Development Asset Team Leader at Arvinas - ApplyBlast

Development Asset Team Leader

Arvinas

2 months ago

4.3 on Glassdoor

Remote

Full Time

Director

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Arvinas is seeking a senior leader to guide cross‑functional oncology development programs from early through late stages. The role leverages deep biological expertise to shape scientific strategy, align internal teams, and represent the asset externally. Reporting to the SVP of Asset Strategy, the leader will drive decision‑making, risk management, and collaboration across clinical, regulatory, CMC, and business functions.

Responsibilities

Lead cross‑functional oncology asset teams through all development phases
Develop and execute integrated long‑range development plans
Represent programs to executive leadership and external stakeholders

Skills

Qualifications

Bachelor's degree in biology or a closely related life science fieldMinimum 15 years of relevant biotechnology/pharmaceutical industry experienceAt least 5 years in a scientific leadership role leading cross‑functional drug development asset teams

About Arvinas

arvinas.com

Headquarters

New Haven, Connecticut, United States

Company Size

201-500 employees

Founded

2013

View Profile

Arvinas is a biotechnology company pioneering targeted protein degradation therapeutics using its proprietary PROTAC (proteolysis-targeting chimera) platform, which designs small molecules that selectively induce degradation of disease-causing proteins rather than merely inhibiting them. The company develops therapies across oncology and neuroscience, and has achieved its first FDA-approved product, VEPPANU (vepdegestrant). Arvinas also partners with leading pharmaceutical companies and academic experts to broaden and accelerate its pipeline of protein degrader treatments.